Primary Care Management of CKD

Nearly 850 million people worldwide are affected by CKD with up to an estimated 97% of these patients remaining undiagnosed. With much of the identification burden falling to primary care physicians, you need to be aware of all known risk factors and the latest diagnostic guidelines to proactively screen for CKD, identify patients at risk, and accurately diagnose and manage this progressive condition.

This independent educational program will provide decision-making support and educational tools to guide practitioners in a real-world clinical context. Patient profiles are presented as simulated scenarios to assist your decision-making in a risk-free environment, enhanced with expert-led discussion and commentary.

Program Director, Kevin Fernando is joined by David Wheeler to take you through each scenario, based upon realistic but complicated cases you may see in your clinic. The education is also available in French, Spanish, Portuguese, Italian, and German.

The infographics and introductory video are also available in Japanese and Chinese.

Just launched

Simulation-based activities

A series of four simulation-based activities provide a practical and safe setting to test your diagnostic capabilities and management decisions in realistic CKD scenarios you may face in your daily practice. Each video scenario looks at different complexities you are likely to face in the management of CKD, considering common comorbidities and patient preferences.

The scenarios are supplemented by a downloadable infographic with the key signs and pitfalls to look out for in patient consultations to ensure early intervention and effective management of CKD.

To select your preferred language please hover and click on the language selector in the bottom right of the screen

Just Launched

CKD with type 2 diabetes

Just Launched

CKD without type 2 diabetes

Just Launched

CKD with comorbid CVD

Coming Soon

CKD and frailty

This independent medical education program will expand upon our current eLearning on the screening, diagnosis, and initial management of chronic kidney disease in primary care.

The content has been developed using feedback from our audience and expert faculty to represent the educational needs most required by the primary care community.

The program is intended for global primary care practitioners. All content will be available in French, Spanish, German, Italian, and Portuguese. The infographic and video will be translated into Japanese and simplified Chinese.

KDIGO – Kidney Disease – Improving Global Outcomes

In collaboration with KDIGO

PCPs participating in the program will be able to:

  • Apply the most recent classification and staging guidelines to achieve earlier diagnosis of CKD
  • Describe how to manage the initial complications and risks associated with a CKD diagnosis, including when to refer to another member of the specialist MDT
  • Incorporate guidelines and evidence-based tools into everyday practice to appropriately manage different CKD patient profiles

 

kevin-fernando-headshot-1by1-white-background

Kevin Fernando

GP Partner North Berwick Health Centre, Scotland, UK

Kevin Fernando is a part-time GP Partner working at North Berwick Health Centre, near Edinburgh, with Specialist Interest in CVRM Medicine & Medical Education.

Dr Fernando is also Scottish lead of the Primary Care Diabetes Society, Content Advisor for WebMD Medscape Global & UK and a co-founder of GoggleDocs.

Dr Fernando graduated from the University of Edinburgh in 2000 and holds both MRCGP and MRCP(UK) qualifications and has completed a Master’s degree in diabetes which he passed with distinction.

Dr Fernando has been elected to Fellowship of the Royal College of General Practitioners, the Royal College of Physicians of Edinburgh and also the Academy of Medical Educators for his work in diabetes and medical education.

Disclosures

Kevin Fernando has received honoraria and/or consultation fees from AstraZeneca, Boehringer Ingelheim, Lilly, Napp, Mundipharma, Menarini, Amarin, Amgen, Daiichi Sankyo, Novo Nordisk, Roche, and Bayer.

David Wheeler

David Wheeler

Professor of Kidney Medicine, University College London, UK

David Wheeler is Professor of Kidney Medicine at University College London, UK, and Honorary Consultant Nephrologist at the Royal Free London NHS Foundation Trust. He is a clinician scientist interested in the complications of chronic kidney disease, specifically those that increase the burden of cardiovascular disease and/or accelerate progression of kidney failure. He has participated in the development and running of several large-scale clinical trials testing lipid-lowering regimens, calcimimetics, SGLT2 inhibitors and HIF stabilisers in patients with chronic kidney disease.

Professor Wheeler’s other roles include Honorary Professorial Fellow of The George Institute and Chair of the International Society of Nephrology Advancing Clinical Trials network. He has been involved in the development of Clinical Practice Guidelines for several organisations, most recently for Kidney Disease: Improving Global Outcomes (KDIGO). He served as KDIGO co-chair between 2012 and 2019. In the UK, he is National Institute of Health Research (NIHR) Renal Specialty Lead and Co-Medical Director of the North Thames NIHR Clinical Research Network.

Disclosures

David Wheeler discloses the following interests: Ongoing consultancy arrangement with AstraZeneca. Honoraria from Amgen, Astellas, Bayer, Boehringer Ingelheim, GSK, Janssen, Napp, Mundipharma, and MSD.

Missed the live webinar? Ondemand webcast available to watch now

This webinar is accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 1 European CME credits (ECMEC®s).

 
Click here to watch the on demand webinar

en_USEnglish